IARPA Funds Team Involving DNA Script, the Broad Institute, and Harvard University for DNA Data Storage Research and Development
15.1.2020 20:10:00 EET | Business Wire | Press release
DNA Script today announced that the company and its Molecular Encoding Consortium partners have been awarded a multi-phase contract worth up to
$23 million from the Intelligence Advanced Research Projects Activity’s (IARPA) Molecular Information Storage (MIST) program. The goal of the project is to develop sequence-controlled polymers as the basis for deployable storage technologies that can eventually scale into the exabyte regime and beyond with reduced physical footprint, power and cost requirements relative to conventional storage technologies.
The Molecular Encoding Consortium is led by the Laboratory of Dr. Robert Nicol at the Broad Institute of MIT and Harvard and includes DNA Script and Professor Donhee Ham’s Research Group at Harvard University. The consortium will explore the possibility of integrating a novel enzymatic DNA synthesis technology and next-generation sequencing into a single instrument over the 4-year duration of the program. The consortium plans to collaborate with Illumina to leverage its sequencing-by-synthesis (SBS) technologies for accurate, low cost decoding.
Massive amounts of digital data are generated every day, and emerging technologies such as autonomous cars and artificial intelligence will further increase the need for data storage at unprecedented scales. This causes major challenges to private and public organizations, which currently rely on exabyte-scale data centers that have large footprints, consume megawatts of power and cost hundreds of millions of dollars to build, operate and maintain over their lifetimes. It is expected that the anticipated growth in data storage requirements cannot be addressed by current resource-intensive technologies. Nucleic acid-based systems hold promise to store this information with radically reduced physical footprints, power and cost requirements.
This technology is not mature yet and will require extensive development to be ready to use. IARPA has therefore launched the MIST program to fund initiatives that could turn molecular-based data storage into reality. The Molecular Encoding Consortium is one of these funded projects.
“This contract with IARPA, which is part of the Office of the Director of National Intelligence, in partnership with prestigious partners such as the Broad Institute and Harvard University is a strong recognition of DNA Script’s results and leadership in developing enzymatic template-free nucleic acid synthesis,” said Dr. Thomas Ybert, CEO of DNA Script. “However, it is only the beginning of this ambitious project, which will require us to push current technological limits to bring to life our cutting-edge technology while also delivering an operational solution to one of the most important challenges of our time.”
“This project at the intersection of molecular biology, physics, chemistry, information theory and electrical engineering leverages the multi-disciplinary capabilities of our laboratory, our exceptional consortium partners and the collaborative nature of our Institute,” said Dr. Robert Nicol, Senior Director of Technology Development at the Broad Institute and the consortium’s Principal Investigator. “The objectives set out by IARPA for this four-year program are ambitious and will require scientific innovations, as well as robust and scalable technologies.”
“The Molecular Encoding Consortium integrates the different experiences and expertise of these leading institutions,” said Dr. Donhee Ham, the Gordon McKay Professor of Electrical Engineering and Applied Physics at Harvard University. “My research group will bring expertise in the interface of solid-state electronic chips and biological systems. I am looking forward to working with the consortium team in combining silicon integrated circuit technology with molecular biology and electrochemistry to tackle this very interesting problem.”
“DNA is the ideal way to store information for long periods of time,” said Dr. Mostafa Ronaghi, Chief Technology Officer of Illumina. “We are excited by the opportunity to collaborate with the early pioneers involved in this project and having our SBS chemistry and instruments used to decode the digital information.”
About IARPA
IARPA invests in high-risk, high-payoff research programs to tackle some of the most difficult challenges of the agencies and disciplines in the Intelligence Community. Additional information on IARPA and its research may be found on www.iarpa.gov.
About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis. The Company’s technology has the potential to greatly accelerate the development of new diagnostics, therapeutics, sustainable chemicals production, improved crops and data storage solutions. www.dnascript.co
About the Dr. Donhee Ham Research Group
Established in 2002, one of the major intellectual focuses of Donhee Ham’s research group has been on directly interfacing silicon integrated circuits with biological systems for applications in neuroscience, neurotechnology, and biomolecular spectroscopy. Notably, his group at Harvard Applied Physics in collaboration with Dr. Hongkun Park’s group at Harvard Chemistry has recently developed a silicon electronic chip with a surface nanoelectrode array that can copy the synaptic connectivity of thousands of connected mammalian neurons. http://ham.seas.harvard.edu
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005627/en/
Contact information
Press contact in the US for DNA Script
Seismic
Eric Schubert
415-939-4366
eric@teamseismic.com
Press contact in Europe for DNA Script
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com
DNA Script Contact
publicrelations@dnascript.com
Illumina Contact
Jen Carroll
jcarroll@illumina.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
